<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466215</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAMAS006420</org_study_id>
    <secondary_id>U01AA025476</secondary_id>
    <nct_id>NCT04466215</nct_id>
  </id_info>
  <brief_title>Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo</brief_title>
  <official_title>Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or&#xD;
      greater severity treated with CORT118335 will report decreased craving for alcohol following&#xD;
      alcohol exposure in the laboratory and report significantly less drinking under naturalistic&#xD;
      conditions, than those treated with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment, Double-Blind, Randomized</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Craving to drink</measure>
    <time_frame>2 weeks</time_frame>
    <description>Visual Analog Scales (VAS) of alcohol craving total score in response to in vivo alcohol cues. Higher scores indicate greater craving severity with a minimum score of 0 and a maximum score of 80.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drinking</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Number of standard drinks per week using the Timeline Followback Interview (TLFB). Total number of alcoholic drinks consumed per week with a minimum value of 0 and an undetermined maximum value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>CORT118335</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>900 mg (6 x 150 mg) tablets daily taken orally for one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six placebo tablets taken orally for one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CORT118335</intervention_name>
    <description>900 mg (6 x 150 mg) tablets taken orally once daily for one week</description>
    <arm_group_label>CORT118335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Six placebo tablets taken orally once daily for one week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female volunteers, 18-75 years of age.&#xD;
&#xD;
          -  Meets DSM-5 criteria for current alcohol use disorder of moderate or greater severity&#xD;
             (AUD-MS).&#xD;
&#xD;
          -  Subjects will not be seeking treatment because the medication studies are not&#xD;
             treatment trials, and to avoid exposing treatment-seekers to alcohol cues.&#xD;
&#xD;
          -  Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the&#xD;
             human lab session.&#xD;
&#xD;
          -  In acceptable health in the judgment of the study physician, based on interview,&#xD;
             medical history, physical exam, ECG, routine urine and blood chemistry.&#xD;
&#xD;
          -  Subjects with a history of depression, who have been on a stable dose of&#xD;
             anti-depressant medication for at least 3 months, and do not meet current DSM-5&#xD;
             criteria for depression or anxiety.&#xD;
&#xD;
          -  All subjects must agree to use double barrier birth control for the study duration and&#xD;
             one month thereafter i.e., males must use condoms and females must use spermicide&#xD;
             and/or a non hormonal barrier method, and their opposite sex partner must likewise use&#xD;
             an effective non hormonal form of contraception.&#xD;
&#xD;
          -  Able to provide informed consent and understand questionnaires and study procedures in&#xD;
             English.&#xD;
&#xD;
          -  Willing to comply with the provisions of the protocol and take daily oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical conditions that could be aggravated by glucocorticoid and/or mineralocorticoid&#xD;
             antagonism.&#xD;
&#xD;
          -  Clinically significant findings on physical exam, ECG, urine or blood tests that may&#xD;
             increase risk.&#xD;
&#xD;
          -  CYP2C19 inhibitors&#xD;
&#xD;
          -  Substrates metabolized primarily by CYP3A, CYP2C9, and CYP2C8 with narrow therapeutic&#xD;
             index&#xD;
&#xD;
          -  BCRP and UGT1A1 substrates&#xD;
&#xD;
          -  Meets DSM-5 criteria for a current major psychiatric disorder, including mood, anxiety&#xD;
             or substance use disorders, other than alcohol, nicotine, or mild cannabis use&#xD;
             disorders.&#xD;
&#xD;
          -  Pregnant or lactating.&#xD;
&#xD;
          -  Treatment within the month prior to screening with (1) an investigational drug, (2)&#xD;
             drugs which may negatively interact with study medications, or (3) drugs that may&#xD;
             influence study outcomes (e.g., disulfiram [Antabuse], naltrexone [ReVia], acamprosate&#xD;
             [Campral], or anticonvulsants.&#xD;
&#xD;
          -  Chronic systemic steroid use&#xD;
&#xD;
          -  Using drugs that are strong inhibitors and inducers of CYP2C9.&#xD;
&#xD;
          -  No fixed domicile and/or no availability by home or mobile telephone.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara J. Mason, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Scripps Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Quello, B.A., B.S.</last_name>
    <phone>858-784-7327</phone>
    <email>squello@scripps.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Bess, MSW</last_name>
    <phone>858-784-7567</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan B Quello, BA, BS</last_name>
      <phone>858-784-7327</phone>
      <email>squello@scripps.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara J Mason, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol-Related Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

